548 related articles for article (PubMed ID: 18976006)
1. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ
Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006
[TBL] [Abstract][Full Text] [Related]
2. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.
Libbrecht L; Severi T; Cassiman D; Vander Borght S; Pirenne J; Nevens F; Verslype C; van Pelt J; Roskams T
Am J Surg Pathol; 2006 Nov; 30(11):1405-11. PubMed ID: 17063081
[TBL] [Abstract][Full Text] [Related]
3. [Expression and clinicopathologic significance of GPC3 and other antibodies in well-differentiated hepatocellular carcinoma].
DU JL; Wei LX; Wang YL
Zhonghua Bing Li Xue Za Zhi; 2011 Jan; 40(1):11-6. PubMed ID: 21429352
[TBL] [Abstract][Full Text] [Related]
4. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma.
Lagana SM; Salomao M; Bao F; Moreira RK; Lefkowitch JH; Remotti HE
Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):170-6. PubMed ID: 22914605
[TBL] [Abstract][Full Text] [Related]
5. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry.
Coston WM; Loera S; Lau SK; Ishizawa S; Jiang Z; Wu CL; Yen Y; Weiss LM; Chu PG
Am J Surg Pathol; 2008 Mar; 32(3):433-44. PubMed ID: 18300806
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression in hepatocellular carcinoma. A clinicopathological analysis with emphasis on diagnostic value.
Wachter DL; Kristiansen G; Soll C; Hellerbrand C; Breuhahn K; Fritzsche F; Agaimy A; Hartmann A; Riener MO
Histopathology; 2012 Jan; 60(2):278-86. PubMed ID: 22211286
[TBL] [Abstract][Full Text] [Related]
7. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum.
Shafizadeh N; Ferrell LD; Kakar S
Mod Pathol; 2008 Aug; 21(8):1011-8. PubMed ID: 18536657
[TBL] [Abstract][Full Text] [Related]
8. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy.
Anatelli F; Chuang ST; Yang XJ; Wang HL
Am J Clin Pathol; 2008 Aug; 130(2):219-23. PubMed ID: 18628090
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma.
Liu H; Li P; Zhai Y; Qu CF; Zhang LJ; Tan YF; Li N; Ding HG
World J Gastroenterol; 2010 Sep; 16(35):4410-5. PubMed ID: 20845507
[TBL] [Abstract][Full Text] [Related]
10. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies.
Cai MY; Tong ZT; Zheng F; Liao YJ; Wang Y; Rao HL; Chen YC; Wu QL; Liu YH; Guan XY; Lin MC; Zeng YX; Kung HF; Xie D
Gut; 2011 Jul; 60(7):967-76. PubMed ID: 21330577
[TBL] [Abstract][Full Text] [Related]
11. Differential diagnostic value of GPC3-CD34 combined staining in small liver nodules with diameter less than 3 cm.
Wang F; Jing X; Wang T; Li G; Li T; Zhang Q; Huang Y; Li J; Wang Y; Gao Y; Han T; Du Z
Am J Clin Pathol; 2012 Jun; 137(6):937-45. PubMed ID: 22586053
[TBL] [Abstract][Full Text] [Related]
12. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.
Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M
Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368
[TBL] [Abstract][Full Text] [Related]
13. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas.
Wang XY; Degos F; Dubois S; Tessiore S; Allegretta M; Guttmann RD; Jothy S; Belghiti J; Bedossa P; Paradis V
Hum Pathol; 2006 Nov; 37(11):1435-41. PubMed ID: 16949914
[TBL] [Abstract][Full Text] [Related]
14. A triple stain of reticulin, glypican-3, and glutamine synthetase: a useful aid in the diagnosis of liver lesions.
Swanson BJ; Yearsley MM; Marsh W; Frankel WL
Arch Pathol Lab Med; 2015 Apr; 139(4):537-42. PubMed ID: 25822763
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical stains of proliferating cell nuclear antigen, insulin-like growth factor 2 and clusterin help distinguish malignant from benign liver nodular lesions.
Lai JP; Chen ZM; Lok T; Chan OT; Himmelfarb E; Zhai Q; Lin F; Wang HL
J Clin Pathol; 2014 Jun; 67(6):464-9. PubMed ID: 24407433
[TBL] [Abstract][Full Text] [Related]
16. Roles of Combined Glypican-3 and Glutamine Synthetase in Differential Diagnosis of Hepatocellular Lesions.
Wasfy RE; Shams Eldeen AA
Asian Pac J Cancer Prev; 2015; 16(11):4769-75. PubMed ID: 26107238
[TBL] [Abstract][Full Text] [Related]
17. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders.
Zhu ZW; Friess H; Wang L; Abou-Shady M; Zimmermann A; Lander AD; Korc M; Kleeff J; Büchler MW
Gut; 2001 Apr; 48(4):558-64. PubMed ID: 11247902
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemistry in the Diagnosis of Hepatocellular Carcinoma.
Choi WT; Kakar S
Gastroenterol Clin North Am; 2017 Jun; 46(2):311-325. PubMed ID: 28506367
[TBL] [Abstract][Full Text] [Related]
19. [Significance of glypican-3 immunohistochemistry in diagnosis of hepatocellular carcinoma].
Yip YC; Wang FH; Vong HT; Zhang M; Wen JM
Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):626-9. PubMed ID: 22177248
[TBL] [Abstract][Full Text] [Related]
20. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma.
Yamauchi N; Watanabe A; Hishinuma M; Ohashi K; Midorikawa Y; Morishita Y; Niki T; Shibahara J; Mori M; Makuuchi M; Hippo Y; Kodama T; Iwanari H; Aburatani H; Fukayama M
Mod Pathol; 2005 Dec; 18(12):1591-8. PubMed ID: 15920546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]